Dana-Farber Cancer Institute - Hematologic Oncology Treatment Center

Boston, Massachusetts 02215-5418

0 studies enrolling now · 1 studies all time

What they study most

Chronic Lymphocytic Leukemia

Studies at this site

• A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period — Running, not enrolling